Synthesis and Development of MSN-Gd3+-C595 as MR Imaging Contrast Agent for Prostate Cancer Cell Imaging
Bita Mehravi, Mehdi Mirzaei, Mehdi S. Ardestani, Massoud Amanlou, Haleh Soltanghoraee, Negar Ghalandarlaki and Seyed Amir Mohsen ZiaeeAffiliation:
Urology and Nephrology Research Center, Shahid Labbafinejad Medical Center, 9th
Boustan, Pasdaran Ave, Tehran, Iran.
Purpose: Cell surface antigens as biomarkers suggest high potential for early diagnosis in cancers. The scope of this study is to synthesize Gd3+
based silica nanoparticles that conjugate on monoclonal antibody C595 by a facile method in order to detect human prostate cancer cells.
Method: In this study, monoclonal antibody C595, anti-MUC-1, was conjugated on Gd3+-based mesoporous silica nanospheres (MSN-Gd3+-C595) (71.1 nm) by utilizing N-5-Azido-2-nitrobenzoyloxy succinimide (ANB-NOS) cross linkers. This contrast agent was characterized using techniques such as nitrogen physisorption, thermogravimetric analysis, scanning and transmission electron microscopy, inductively coupled plasma atomic emission spectrometry (ICP-AES) and Dynamic Light Scattering (DLS). The relaxivities were determined using a 3 Tesla MRI scanner. The accurate and easily available in vitro assay based on MSN-Gd3+-C595 was applied to identify the cell surface antigen expression in the case of prostate cancer cells and the quantitative data were analyzed.
Results: Results showed that N-5-Azido-2-nitrobenzoyloxysuccinimide cross-linkers were suitable for conjugation of C595 on the surface of mesoporous silica nanospheres. Protein measurement assay indicated that 8% antibodies were attached on the surface of mesoporous silica nanospheres and TGA and ICP-AES results demonstrated that 19 wt% Gd3+-DTTA were loaded into C595-MSN-Gd3+. Furthermore, the obtained data showed a powerful relaxations as well as selective MUC-1 antigen binding to the cell.
Conclusion: Based on the results of the present study, MSN-Gd3+-C595 nanoprobe may be a potential prostate molecular imaging and may provide critical guideline in selecting these nanoparticles as an appropriate contrast agent for nanomedicine applications.
Prostate cancer cells, gadolinium, Mab C595, mesoporous silica nanospheres, MRI.
Download Free Order Reprints Order Eprints Rights and Permissions